Background/Aim: Mortality resulting from cardiovascular disease in patients with end-stage renal disease (ESRD) is high. In this study we sought to investigate the clinical value of the malnutrition-inflammation-atherosclerosis (MIA) syndrome for long-term prediction of cardiovascular mortality in patients treated with ESRD. Methods: A total of 42 ESRD patients on hemodialysis were enrolled. Inflammatory markers and nutritional parameters were determined. Carotid atherosclerosis was investigated by ultrasonographically evaluated carotid intima-media thickness (cIMT). Mortality was evaluated at a 5-year follow-up. Results: No correlation was evident between nutritional markers and inflammatory indexes. cIMT was inversely correlated with predialysis serum albumin. In the overall population of 42 patients, 11 (26.2%) died of cardiovascular causes during follow-up. Kaplan-Meier survival curves indicate that cIMT (≧0.9 mm), C-reactive protein (CRP) (>1 mg/dl), and serum albumin (<3.5 g/dl) predict cardiovascular death in patients with ESRD. Conclusions: We have demonstrated that cIMT, CRP and serum albumin predict long-term mortality in ERSD patients. Our study suggests that further investigation of the MIA syndrome will provide insights into the susceptibility to CVD in this patient group.

1.
Sarnak MJ: Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003;41:c11–c17.
2.
Goldsmith DJ, Covic A: Coronary artery disease in uremia: etiology, diagnosis, and therapy. Kidney Int 2001;60:c2059–c2078.
3.
Collins AJ, Li S, Ma JZ, Herzog C: Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 2001;38:c26–c29.
4.
Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:c458–c482.
5.
Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis JH: Immunologic function and survival in hemodialysis patients. Kidney Int 1998;54:c236–c244.
6.
Stenvinkel P, Heimburger O, Lindholm B, Kaysen GA, Bergstrom J: Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000;15:c953–c960.
7.
Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM: Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney Int 1999;55:c1945–c1951.
8.
Bayes B, Pastor MC, Bonal J, Junca J, Hernandez JM, Riutort N, Foraster A, Romero R: Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant 2003;18:c106–c112.
9.
Racki S, Zaputovic L, Mavric Z, Vujicic B, Dvornik S: C-reactive protein is a strong predictor of mortality in hemodialysis patients. Ren Fail 2006;28:c427–c433.
10.
Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Stancanelli B, Nicocia G, Buemi M: Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. J Intern Med 2003;254:c132–c139.
11.
Hung CY, Chen YA, Chou CC, Yang CS: Nutritional and inflammatory markers in the prediction of mortality in Chinese hemodialysis patients. Nephron Clin Pract 2005;100:c20–c26.
12.
Herget-Rosenthal S, Marggraf G, Pietruck F, Husing J, Strupat M, Philipp T, Kribben A: Procalcitonin for accurate detection of infection in haemodialysis. Nephrol Dial Transplant 2001;16:c975–c979.
13.
Bergstrom J: Nutrition and mortality in hemodialysis. J Am Soc Nephrol 1995;6:c1329–c1341.
14.
Detsky AS, Baker JP, O’Rourke K, Johnston N, Whitwell J, Mendelson RA, Jeejeebhoy KN: Predicting nutrition-associated complications for patients undergoing gastrointestinal surgery. J Parenter Enteral Nutr 1987;11:c440–c446.
15.
Goulet J, Nadeau G, Lapointe A, Lamarche B, Lemieux S: Validity and reproducibility of an interviewer-administered food frequency questionnaire for healthy French-Canadian men and women. Nutr J 2004;3:13.
16.
Stenvinkel P: Inflammation in end-stage renal disease: the hidden enemy. Nephrology 2006;11:c36–c41.
17.
Nascimento MM, Pecoits-Filho R, Qureshi AR, Hayashi SY, Manfro RC, Pachaly MA, Renner L, Stenvinkel P, Lindholm B, Riella MC: The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. Nephrol Dial Transplant 2004;19:c2803–c2809.
18.
Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993;329:c1001–c1006.
19.
Leavey SF, Strawderman RL, Jones CA, Port FK, Held PJ: Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis 1998;31:c997–c1006.
20.
Kaysen GA, Dubin JA, Muller HG, Mitch WE, Rosales LM, Levin NW: Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int 2002;61:c2240–c2249.
21.
Djousse L, Rothman KJ, Cupples LA, Arnett DK, Ellison RC; NHLBI Family Heart Study: Relation between serum albumin and carotid atherosclerosis: the NHLBI Family Heart Study. Stroke 2003;34:c53–c57.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.